- Conditions
- Cardiovascular Disease, Coronary Artery Bypass Surgery
- Interventions
- Heparin, Bivalirudin
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 445
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small Cell Lung Cancer
- Interventions
- Etoposide, Cisplatin, enoxaparin sodium
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Peabody, Massachusetts
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Computerized Tomography scan, Single Photon Emission Computed Tomography scans, Technetium Tc 99M, Planar Images, Esophagogastroduodenoscopy
- Radiation · Drug · Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
- Interventions
- Alteplase 50 MG [Activase]
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more
- Conditions
- Blood Pressure, Hypertension
- Interventions
- Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
- Interventions
- bivalirudin
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Catheter-Related Infections
- Interventions
- 25% ethanol, heparin lock
- Drug · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Thrombocytopenia, Thrombosis
- Interventions
- Argatroban
- Drug
- Lead sponsor
- Encysive Pharmaceuticals
- Industry
- Eligibility
- Up to 16 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- ONCObind (Onco-Seraph) 100 Filter
- Device
- Lead sponsor
- ExThera Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Peripheral Artery Disease
- Interventions
- Contrast Injection, Dextran Injection, CO2 Injection, Heparinized Normal Saline Injection
- Procedure
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Dalteparin
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Evanston, Illinois • St Louis, Missouri + 6 more
- Conditions
- Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm, Pathologic Fracture, Plasma Cell Myeloma, Soft Tissue Sarcoma
- Interventions
- Dalteparin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pulmonary Embolism
- Interventions
- FlowTriever System, Anticoagulation Agents
- Device · Drug
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
- Conditions
- Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma, Wilms' Tumor, Neuroblastoma
- Interventions
- ODSH
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Extracorporeal Membrane Oxygenation Complication
- Interventions
- Heparin Sodium, Bivalirudin Injection [Angiomax]
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Deep Venous Thrombosis
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
- Conditions
- Oral Anticoagulation
- Interventions
- Not listed
- Lead sponsor
- Abbott RDx Cardiometabolic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Loma Linda, California • Sacramento, California • San Diego, California + 1 more
- Conditions
- Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
- Interventions
- Angiomax (bivalirudin) anticoagulant
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Venous Thromboembolism, Postpartum
- Interventions
- Dalteparin Sodium
- Drug
- Lead sponsor
- Ottawa Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Charlottesville, Virginia • Seattle, Washington
- Conditions
- Arteriovenous Access Fistula Stenosis
- Interventions
- Paclitaxel, Standard Therapy
- Drug · Procedure
- Lead sponsor
- Englewood Hospital and Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Englewood, New Jersey
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
- Interventions
- Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 151
- States / cities
- Chula Vista, California • Fremont, California • Fresno, California + 104 more
- Conditions
- Thrombosis
- Interventions
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 28 Days to 17 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more